Summary: New preclinical research indicates that psilocin—the active metabolite produced when the psychedelic psilocybin is metabolized—can reduce alcohol consumption by calming stress-sensitive neurons in the central amygdala. In female mice exposed to prolonged alcohol intake, psilocin lowered hyperactivity of these neurons and produced a temporary decrease in drinking. These findings help clarify how psychedelic-based interventions might influence brain circuits linked to addiction and stress.
The effects were also observed in animals with milder alcohol exposure, paralleling clinical reports that psychedelics can improve emotional regulation across a variety of psychiatric conditions. By linking behavioral changes in ethanol consumption to specific activity changes in central amygdala neurons, the study offers mechanistic insight that may inform future therapeutic development for alcohol use disorder and stress-related psychiatric illnesses.
Key Facts
- Stress circuit target: Psilocin reduced activity of central amygdala neurons involved in alcohol use, anxiety, and depression.
- Reduced drinking: The transient decrease in neuronal activity coincided with reduced voluntary ethanol intake while psilocin was active.
- Mechanistic insight: Results support growing evidence that psychedelics can modulate emotional regulation circuits across diverse psychiatric disorders.
Source: SfN
A mushroom-derived psychedelic metabolite shows promise for treating alcohol use disorder
Psilocin, the compound produced in the body after taking psilocybin, has attracted attention for its potential therapeutic effects. Although clinical studies suggest psilocybin can lower alcohol use in some people, the neural mechanisms behind these effects have remained unclear. Researchers led by Sarah Magee and Melissa Herman at the University of North Carolina at Chapel Hill investigated whether psilocin acts on neurons in the central amygdala—a brain region central to emotional processing and stress responses—to change alcohol consumption behaviors.
The research focused on female mice because female rodents in these models typically consume more alcohol than males. Using targeted measures of neuronal activity and voluntary ethanol intake, the team found that psilocin acutely reduced activity in central amygdala neurons that express corticotropin-releasing factor receptor 1 (CRF1) following chronic alcohol exposure. This suppression of hyperactive neurons was associated with a temporary drop in ethanol drinking while the drug’s effects persisted. When psilocin was no longer active, drinking levels returned toward baseline in subsequent sessions.
Importantly, comparable effects were observed in mice subjected to a less severe model of alcohol exposure. This consistency supports the idea that psilocin’s modulation of stress-related circuits could underlie broader clinical benefits reported for psychedelic therapies, including improvements in anxiety, depression, and maladaptive stress responses that often co-occur with alcohol use disorder.
Melissa Herman notes that controlled preclinical experiments are essential for filling knowledge gaps about how psychedelics act on specific brain circuits. “It makes sense that dampening this neuron population reduces drinking because increased activity in these neurons is associated with alcohol use disorders,” she explains. “These neurons also play a role in depression and anxiety, areas where psychedelics are showing therapeutic promise, so our findings provide mechanistic context for those effects as well.”
Key Questions Answered:
A: Psilocin reduced hyperactivity of central amygdala CRF1-expressing neurons after long-term ethanol exposure, and this reduction coincided with a short-term decrease in alcohol drinking in female mice.
A: Yes. Similar reductions in neuronal activity and ethanol consumption were observed in animals with both severe and milder chronic alcohol exposure.
A: The study provides mechanistic evidence that psilocin engages central amygdala circuits linked to stress and emotional regulation, offering a plausible pathway by which psychedelics might reduce problematic drinking and ameliorate symptoms of anxiety and depression.
About this AUD and psychopharmacology research news
Author: SfN Media
Source: SfN
Contact: SfN Media – SfN
Image: The image is credited to Neuroscience News
Original Research: Closed access.
“The Psychedelic Psilocin Suppresses Activity of Central Amygdala Corticotropin Releasing Factor Receptor 1 Neurons and Decreases Ethanol Drinking in Female Mice” by Sarah Magee et al., Journal of Neuroscience. DOI: 10.1523/JNEUROSCI.0652-25.2025
Abstract
The Psychedelic Psilocin Suppresses Activity of Central Amygdala Corticotropin Releasing Factor Receptor 1 Neurons and Decreases Ethanol Drinking in Female Mice
Alcohol use disorder (AUD) remains a common condition with limited effective treatments. The central amygdala (CeA) is a key node in the brain’s stress and emotional networks, and dysregulation of the corticotropin-releasing factor (CRF) system within the CeA is associated with AUD pathology. CRF1 receptors in the CeA influence alcohol drinking and have been explored as therapeutic targets.
Psilocybin has shown promise in some clinical studies for reducing alcohol consumption, but effects are inconsistent and the underlying neurobiological mechanisms are not well defined. Because psilocybin is metabolized to psilocin, which can act on multiple brain regions including the CeA, the authors investigated whether psilocin alters voluntary ethanol drinking and CeA CRF1 neuronal activity.
In controlled mouse models, psilocin produced an acute decrease in ethanol consumption across two models of chronic ethanol exposure while leaving locomotor behavior unchanged. In ethanol-naïve female CRF1:GFP mice, psilocin increased overall CeA activation but lowered relative CRF1 activation in CeA subregions. Similar patterns of reduced CRF1 activation were observed in chronically ethanol-exposed mice at 24- and 72-hour withdrawal time points. Psilocin also raised corticosterone at the 24-hour withdrawal mark but not at 72 hours.
Taken together, these results indicate that psilocin engages central amygdala circuitry and reduces relative CRF1 neuron activation in parallel with short-term reductions in drinking. These preclinical findings advance understanding of how psilocin may influence stress-related brain circuits and help interpret emerging clinical observations about psychedelic therapies for AUD and related psychiatric conditions.